The disclosure relates to a flexible active species generator comprising: a first electrode of a conductive metal thin film; a second electrode of a ground electrode; a flexible dielectric layer of an insulator formed between the first electrode and the second electrode; and a plasma resistant functional layer formed between the dielectric layer and the second electrode, wherein the first electrode and the second electrode are electrically connected to an external power supply to generate an atmospheric pressure plasma to generate active species. The flexible active species generator has a plasma resistant function to prevent deformation and decomposition of an insulator caused by the plasma as well as an active species generating function from atmospheric pressure plasma, and has durability and safety, which is thus applicable to articles, foods, garments and human body in various forms.

A transdermal delivery system (1) configured to deliver an active agent to human or animal tissue, comprising a penetrative electrode (2) of one polarity that provides an electrical contact (3) beneath the stratum corneum (20); a surface electrode (4) of the opposite polarisation to that of the penetrative electrode (2) that provides an electrical contact to the external surface of the skin (21) on the opposite side of the stratum corneum (20) to the electrical contact (3) of the penetrative electrode (2); a dispenser (5) configured to deliver of an active agent to the external surface of the skin (21) adjacent to an electrical contact of the surface electrode (4); a method of delivering the active agent to the tissue of a human or animal body using the transdermal delivery system (1) and an electrode assembly (10) for use in preparing the transdermal delivery system (1).

An external defibrillator system such as a WCD is also capable of providing transthoracic pacing and drug delivery (e.g., pain-reducing drugs and/or a sedatives) to a patient. The drug(s) may be included in the therapy electrode electrolyte and dispensed for defibrillation, cardioversion and/or pacing therapy. Alternatively, the drug(s) may be stored in a separate reservoir and dispensed during pacing therapy. The drug(s) may be dispensed to a patient after a successful defibrillation therapy. The pacing therapy may be delivered a set time-period after the drug(s) were dispensed. A relatively small electric current may be delivered to the area of the patient on which the drug(s) were dispensed to facilitate drug absorption.

An oral appliance for the treatment of sleep disorders, such as obstructive sleep apnea, in a user is presented. The oral appliance may include a mouthpiece configured to receive a user's dentition. The mouthpiece may include an oxygen sensor, a pressure sensor, an airflow sensor, an actigraphy sensor, a noise detector, and at least one stimulator for providing stimulation to a user's tongue in the event of decreased oxygen saturation levels, increased pressure applied to occlusal surfaces of the user's dentition, decreased actual airflow levels and/or increased noise levels. The mouthpiece may be provided with pharmaceutical compound reservoirs that deliver pharmaceutical compounds to the oral mucosa of the user, which compounds treat symptoms of sleep apnea. The mouthpiece may further include a microprocessor that receives data from the oxygen sensor, pressure sensor, airflow sensor, actigraphy sensor and noise detector, and activates the at least one stimulator and/or pharmaceutical compound reservoirs.

An electroporation probe has a housing supporting needles electrically linked to a coupler for an electrical drive. A cap has apertures in a distal face and aligned with the needles. The cap is movable longitudinally against a spring bias relative to the needles to allow insertion by the needles in use as the cap is pressed against patient tissue. There is a limit feature for abutting a limiter setting maximum extent of longitudinal movement relative to the housing. This allows the probe to be presented by the physician without the needles protruding and for them to be inserted up to the user-set maximum extent with maintenance of spacings due to the guiding action of the cap pressed against the tissue surface.

Methods of using an apparatus for generating dielectrophoretic electromagnetic fields (dc-DEP EMF) to enhance cell polarity through the application of dc-DEP EMF force to stabilize Hyaluronan Mediated Motility Receptor (HMMR) and differentially modulate its expression in cancerous and noncancerous cells. A significant down regulation of HMMR when coupled with the decreased cell growth/mitosis and decreased mitotic spindle formation in treated human breast carcinoma cells indicating a decreased cell motility/migration/metastasis occurs when the cancerous cells are exposed to the dc-DEP EMF force. An improved apparatus for generating dielectrophoretic electromagnetic fields comprising crystals in the center of the orb for enhanced bio-field, a power supply toroidal flow of direct current to the orb, sensing capabilities to measure impedance, and customization of electromagnetic signals emitted by the apparatus and the power supply.

The present technology includes systems and methods for treating pain by pulsing heat into a volume of tissue containing thermoreceptors. The pulsed heat may be configured to induce stimulation of thermoreceptors. The pulsed heat may also be applied at a frequency configured to induce desensitization of at least a subset of the thermoreceptors.

Methods for electrical modulation of inflammation or serum TNF levels in a subject.

High-frequency irreversible electroporation (H-FIRE) is an electroporation-based therapy used to ablate cancerous tissue. Treatment consists of delivering short pulses in a series of bursts. Reducing pulse duration leads to reduced treatment volumes compared to traditional IRE, therefore larger voltages are typically applied to generate ablations comparable in size. Administration of adjuvant calcium enhances ablation area in vitro for H-FIRE treatments of several pulse durations. Furthermore, H-FIRE treatment delivered with CaCl.sub.2 results in cell death thresholds higher than that of H-FIRE without calcium and comparable to IRE thresholds without calcium. Quantifying the reversible electroporation threshold revealed that CaCl.sub.2 enhances the permeabilization of cells compared to a NaCl control. H-FIRE treatment with calcium enhances the IRE to thermal cell death ratio, thereby also enhancing the positive immune response from treatment.

Techniques for High-Frequency Irreversible Electroporation (HFIRE) using a single-pole tine-style internal device communicating with an external surface electrode are described. In an embodiment, a system for ablating tissue cells in a treatment region of a patient's body by irreversible electroporation without thermally damaging the tissue cells is described. The system includes at least one single-pole electrode probe for insertion into the treatment region, the single-pole electrode probe including one or more tines. The system further includes at least one external surface electrode for placement outside the patient's body and configured to complete a circuit with the single-pole electrode probe. The system also includes a control device for controlling HFIRE pulses to the single-pole tine-style electrode and the skin-surface electrode for the delivery of electric energy to the treatment region. Other embodiments are described and claimed.